on major coronary events in hypercholesterolaemic patients (JELIS): a Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded. Significant reduction in residual risk in patients treated with statins. Results from the JELIS (Japan EPA Lipid Intervention Study) trial. EPA may have beneficial.
|Published (Last):||10 March 2004|
|PDF File Size:||18.29 Mb|
|ePub File Size:||2.54 Mb|
|Price:||Free* [*Free Regsitration Required]|
EPA is a promising treatment for prevention of major coronary events, and especially non-fatal coronary events, in Japanese hypercholesterolaemic patients. Further detailed data assessment by Amarin and regulatory authorities will continue and take several months to complete and record The final evaluation of the totality of the efficacy and safety data from REDUCE-IT may include some or all of the following, as well as other considerations: The trial population was Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease.
Epidemiological and clinical evidence suggests that an increased intake of long-chain n-3 fatty acids protects against mortality from coronary artery disease.
Most patients at baseline were taking at least one other cardiovascular medication including anti-platelet agents No head-to-head cardiovascular outcomes study of EPA vs a mixture of omega-3 acids has been conducted. CI denotes confidence interval.
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia [published online ahead of print November 10, ]. Selected additional baseline risk factors included hypertension Prespecified hierarchical testing of other secondary endpoints revealed significant reductions in the following:.
Other cardiovascular outcomes trials that studied fish oil or mixtures of omega-3 acids that include the omega-3 acid, DHA, have reported negligible impact on cardiovascular events. GISSI-P is an open-label outcomes trial 1 g omega-3 fatty acid mixtureconducted in Italy, that supported the hypothesis that omega-3 fatty acids likely exert their cardioprotective effects through nonlipid-mediated mechanisms.
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Patients enrolled were treated with statin therapy at baseline with most At mean follow-up of 4. While the DMC noted variation in LDL-C measurements in both arms and that a small physiological effect of mineral oil might be possible, the DMC concluded that it was not possible to determine if the LDL-C increase in the placebo arm was a natural increase over time or due to the mineral oil, they found no apparent effect on outcomes and found that this small change was unlikely to explain the observed benefit of VASCEPA over placebo.
Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid EPA in atherosclerosis. GISSI-P did not suggest an effect on the incidence of nonfatal cardiovascular events and the effects of omega-3 fatty acids on lipids, including serum TGs, were negligible. Void where prohibited by law, taxed, or restricted.
Patients were randomly assigned 1: These observations suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering.
Eligible patients include those who participate in commercial insurance, through a healthcare exchange, or pay cash.
Mineral oil placebo consideration and analysis. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other jekis events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting.
Watch the national commercial.
Amarin, through its dedicated team of professionals, constantly seeks to improve patient care through stuxy actions and products while also striving to continuously improve along the way. N Engl J Med. Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events.
The median age at baseline was 64 years range: Nat Clin Pract Melis Med. Am J Cardiovasc Drugs. The median change in LDL-C was 3.
VASCEPA® (icosapent ethyl) | REDUCE-IT™ Results Announced
The median follow-up duration was 58 months 4. While overall adverse event rates were similar across treatment groups Numerically more serious adverse events related to bleeding; overall rates were low 2. The Kaplan-Meier estimates of the cumulative incidence of the primary and key secondary composite endpoints over time are shown in Figure 1 and Figure 2 below. Adverse events and serious adverse events leading to study drug discontinuation were similar to placebo.
The study was registered at ClinicalTrials. On stable background lipid-lowering therapy, the median [Q1, Q3] fasting TG was